Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have improved survival in many cancers, but they cause distinct types of kidney injury. This narrative review, based on a structured literature search, focuses on these two drug classes and is built around three clinical messages. The first is the renal-oncologic paradox: therapies that extend survival may leave a growing number of patients living with chronic kidney disease, so long-term renal follow-up is needed. The second is divergent management: ICI-associated acute kidney injury occurs in about 2–5% of treated patients, is usually acute tubulointerstitial nephritis, and is treated by withholding the ICI and giving corticosteroids. In contrast, kidney injury from VEGF-pathway inhibition is structural and hemodynamic (hypertension, proteinuria, podocytopathy, and thrombotic microangiopathy mainly with VEGF ligand blockade) and is managed with blood pressure control, renin–angiotensin system blockade, and dose modification rather than immunosuppression. The third is the role of cystatin C: creatinine-based eGFR can overestimate kidney function in patients with cachexia or sarcopenia, and cystatin C-based eGFR may improve the detection of kidney injury and drug dosing. We also briefly discuss emerging agents and patients with pre-existing chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: